Studienregister

Studienregister der Deutschen Gesellschaft für Urologie e.V.

AN 26/07

PrüfplancodeISRCTNEudraCTClinicaltrials.govDRKS

Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma

Status: Aktiv

Studienziel / Fragestellung

Diagnose

Patientenmerkmale

Stadium

Fortgeschritten

Alter

18-100

Einschlusskriterien

- Age 18 or older
- Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC)
- Majority component of conventional clear-cell type is mandatory
- At least 1 measurable lesion (per RECIST)

Ausschlusskriterien

- Prior systemic treatment for RCC
- Evidence of current or prior central nervous system (CNS) metastases
- Significant cardiovascular disease
- Pregnant or nursing women Additional criteria applies

Studiendesign

  • Phase III
  • Multizentrisch
  • Prospektiv
  • Randomisiert
  • Zweiarmig
  • Open Label

Intervention

Bevacizumab (Avastin®) + Temsirolimus (Torisel®)

versus

Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®)

Dokumente (passwortgeschützt)

Zuständigkeiten Gesamtstudie

Leiter der klinischen Prüfung

Prof. Dr. med. Jürgen Gschwend

nach oben